Surface modified PLGA nanoparticles for brain targeting of Bacoside-A

Area of Science:

• Nanotechnology
• Neuroscience
• Pharmacology

Background:

• Neurodegenerative disorders like Alzheimer's Disease pose significant treatment challenges.
• Effective drug delivery to the brain is hindered by the blood-brain barrier (BBB).
• Bacoside-A is a neuroprotective compound with potential therapeutic benefits.

Purpose of the Study:

• To develop and characterize poly-(D,L)-Lactide-co-Glycolide (PLGA) nanoparticles for brain delivery of Bacoside-A.
• To enhance the brain targeting of Bacoside-A by modifying nanoparticle surfaces.
• To evaluate the in vitro and in vivo efficacy of these nanoparticles for neurodegenerative disorder treatment.

Main Methods:

• PLGA nanoparticles loaded with Bacoside-A were prepared using the o/w emulsion solvent evaporation technique.
• Nanoparticle surfaces were coated with polysorbate 80 to improve blood-brain barrier (BBB) penetration.
• Optimization of processing parameters (sonication time, polymer/surfactant concentration, drug-polymer ratio) was performed for high yield.
• In vitro characterization included size, polydispersity index, encapsulation efficiency, drug loading, morphology (SEM), crystallinity (X-ray), and drug release studies.
• In vivo brain targeting was assessed in Wistar albino rats by measuring brain Bacoside-A concentration.

Main Results:

• Optimized nanoparticles were in the nanosized range (70-200 nm) with a low polydispersity index (0.391 ± 1.2).
• Encapsulation efficiency was 57.11 ± 7.11% with a drug loading capacity of 20.5 ± 1.98%.
• SEM confirmed spherical morphology, and X-ray studies indicated no drug-polymer chemical interaction.
• Sustained in vitro release of Bacoside-A was observed, reaching up to 83.04 ± 2.55% in 48 hours.
• In vivo studies showed a significantly higher brain concentration of Bacoside-A (23.94 ± 1.74 μg/g tissue) compared to the pure drug (2.56 ± 1.23 μg/g tissue).

Conclusions:

• Surface-modified PLGA nanoparticles demonstrate significant potential for targeted Bacoside-A delivery to the brain.
• This approach offers a promising strategy for the treatment of neurodegenerative disorders.
• The optimized nanoparticles effectively overcome the BBB, enhancing therapeutic efficacy.